Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ During this past weekend s 20th biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Susan M. O Brien, MD, and Catherine J..